Perspective Therapeutics, Inc. (CATX) Earnings History
Net Loss32 years of earnings data (1994–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Perspective Therapeutics, Inc. (CATX) Earnings Overview
As of June 29, 2026, Perspective Therapeutics, Inc. (CATX) reported trailing twelve-month net income of -$111M, reflecting -13.8% year-over-year growth. The company earned $-1.07 per diluted share over the past four quarters.
Looking at the long-term picture, CATX's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 1999.
Perspective Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AGEN ($65M net income, 0.1% margin), RNW ($10.40B net income, 7.9% margin), LNTH ($279M net income, 15.2% margin), CATX has comparable earnings metrics. Compare CATX vs AGEN →
CATX Earnings vs Peers
Earnings metrics vs comparable public companies
CATX Historical Earnings Data (1994–2025)
32 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$103M | -30.1% | -$114M | $-1.40 | - | - |
| 2024 | -$79M | -70.5% | $10M | $-1.23 | - | - |
| 2023 | -$47M | -217.0% | -$41M | $-0.85 | -3243.2% | -2855.0% |
| 2022 | -$15M | -105.1% | -$15M | $-0.27 | -206.5% | -213.7% |
| 2021 | -$7M | -124.4% | -$7M | $-0.13 | -66.3% | -68.5% |
| 2020 | -$3M | +2.5% | -$3M | $-0.06 | -31.7% | -34.2% |
| 2019 | -$3M | +32.6% | -$3M | $-0.05 | -33.8% | -35.9% |
| 2018 | -$5M | +27.6% | -$5M | $-0.07 | -66.3% | -72.2% |
| 2017 | -$7M | -8.7% | -$7M | $-0.12 | -113.1% | -113.6% |
| 2016 | -$6M | -30.8% | -$6M | $-0.11 | -129.4% | -132.5% |
| 2015 | -$5M | -28.0% | -$5M | $-0.09 | -98.8% | -106.6% |
| 2014 | -$4M | +38.2% | -$4M | $-0.07 | -79.9% | -94.1% |
| 2013 | -$6M | -54.5% | -$5M | $-0.14 | -141.2% | -108.7% |
| 2012 | -$4M | -10.5% | -$4M | $-0.11 | -85.2% | -89.9% |
| 2011 | -$3M | -22.8% | -$4M | $-0.12 | -68.8% | -71.0% |
| 2010 | -$3M | +29.5% | -$3M | $-0.11 | -54.3% | -56.6% |
| 2009 | -$4M | +34.5% | -$4M | $-0.18 | -76.3% | -75.8% |
| 2008 | -$6M | +28.0% | -$6M | $-0.27 | -113.7% | -119.4% |
| 2007 | -$9M | +10.9% | -$9M | $-0.37 | -119.5% | -123.0% |
| 2006 | -$10M | -16.9% | -$10M | $-0.54 | -167.4% | -169.0% |
| 2005 | -$8M | -92.5% | -$7M | $-0.68 | -412.1% | -360.8% |
| 2004 | -$4M | -7012.1% | -$4M | $-0.76 | -2116.3% | -1974.5% |
| 2003 | $-60,027 | -1.6% | $-19,022 | $-0.07 | - | - |
| 2002 | $-59,084 | -125.1% | $-7,584 | $-0.18 | - | - |
| 2001 | $235,110 | +458.1% | $-15,569 | $0.60 | - | - |
| 2000 | $-65,649 | -103.6% | $-14,149 | $-0.20 | - | - |
| 1999 | $2M | +1407.5% | $-15,530 | $5.41 | - | - |
| 1998 | $-139,549 | +67.2% | $-222,825 | $-0.42 | - | - |
| 1997 | $-426,078 | +80.2% | $-260,710 | $-1.29 | -5.4% | -3.3% |
| 1996 | -$2M | -129.1% | -$2M | $-6.63 | -26.1% | -25.5% |
| 1995 | $-939,169 | -114.6% | $-827,942 | $-3.27 | -12.0% | -10.6% |
| 1994 | $-437,594 | - | -$1M | $-1.52 | -6.4% | -17.2% |
Download Data
Export CATX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
32+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CATX — Frequently Asked Questions
Quick answers to the most common questions about buying CATX stock.
What is CATX earnings per share (EPS)?
CATX trailing twelve-month (TTM) diluted EPS is $-1.07, reflecting -13.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1994 to 2025 is available in the table on this page.
What is Perspective Therapeutics, Inc.'s net income?
Perspective Therapeutics, Inc. (CATX) trailing twelve-month net income is $-111M as of 2025. Earnings declined -13.8% year-over-year.
Is CATX profitable?
CATX is not currently profitable on a TTM basis, reporting a net loss of $-111M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CATX's earnings growth rate?
CATX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1994 to 2025.
What are CATX's profit margins?
Perspective Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -41.4%.
Is CATX growing earnings?
CATX earnings are declining — EPS fell -13.8% year-over-year. TTM net income dropped to $-111M. This contrasts with the 5-year CAGR of N/A.
What was CATX's best earnings year?
Perspective Therapeutics, Inc.'s highest annual net income on record is $2M, achieved in fiscal year 1999. Earnings history on this page spans 1994 to 2025 and includes all annual and quarterly figures.
What were CATX's earnings last quarter?
CATX's most recent reported quarter was Q1 2026. Net income was $-26M with diluted EPS of $-0.25. For a full breakdown of all quarters, see the quarterly earnings table on this page.